UMBRALISIB MONOTHERAPY DEMONSTRATES EFFICACY AND SAFETY IN PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA: A MULTICENTER, OPEN‐LABEL, REGISTRATION DIRECTED PHASE 2 STUDY. (12th June 2019) - Zinzani, P.; Samaniego, F.; Jurczak, W.; Lech‐Maranda, E.; Ghosh, N.; Anz, B.; Patten, P.; Reeves, J.; Leslie, L.A.; Smolewski, P.; Chavez, J.C.; Scarfo, L.; et al.